SOURCE: Nutrition 21, Inc.

Nutrition 21, Inc.

April 20, 2011 01:00 ET

New Study Shows Supplementation With Nutrition 21's Chromium May Help Protect the Brain From Damage Caused by Insulin-Induced Hypoglycemia

PURCHASE, NY--(Marketwire - Apr 20, 2011) - Nutrition 21, Inc. (OTCBB: NXXI), the developer and marketer of clinically substantiated ingredients for dietary supplements, foods and beverages, and animal nutrition, today announced the results of a preclinical study showing its chromium histidinate helps protect the brain from damage caused by hypoglycemia (or very low blood sugar) induced by a high dose of insulin. The results of the study titled "Chromium Histidinate Reduces Brain Damage caused by Insulin-induced Hypoglycemia" were presented last week at the Federation of American Societies for Experimental Biology (FASEB) annual meeting in Washington, D.C.

Hypoglycemia occurs when blood glucose levels become abnormally low; causing an inadequate supply of glucose to the brain that can result in impaired cognitive function, unconsciousness, brain damage or even death. Researchers at Firat University tested the ability of chromium histidinate to protect the brain against hypoglycemia caused by a high "overdose" of injected insulin. They found that rats fed chromium histidinate prior to the insulin injection had significantly less insulin-induced brain damage compared to the untreated control group.

Insulin-induced hypoglycemia is a significant safety concern in people who use insulin as a treatment of diabetes. "These study results showed that administration of chromium histidinate helped protect the brain from damage caused by an overdose of insulin," stated James Komorowski, Vice President, Research & Development at Nutrition 21, Inc. The results of this study provide evidence to support further evaluation of the use of Nutrition 21's patented chromium as an adjunctive treatment to insulin. "A reduction in the incidence and/or severity of insulin-induced hypoglycemia would have significant value to people with diabetes who use insulin on a daily basis," added Mr. Komorowski.

About Nutrition 21
Nutrition 21, Inc. (OTCBB: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and holds over 70 issued and pending patents for dietary supplement ingredients, including chromium picolinate, and combinations of chromium compounds with other ingredients. Its products are sold to leading dietary supplement, functional food and beverage, and animal nutrition manufacturers. For more information please visit http://www.nutrition21.com.

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2010. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Contact Information

  • Company Contact:
    James Komorowski, M.S., C.N.S.
    Vice President
    914-701-4500

    Investor Contact:
    Alan Kirschbaum
    Chief Financial Officer
    914-701-4500